Cuthbertson, Daniel J 
ORCID: 0000-0002-6128-0822, Barriuso, Jorge, Lamarca, Angela, Manoharan, Prakash, Westwood, Thomas, Jaffa, Matthew, Fenwick, Stephen W, Nuttall, Christina, Lalloo, Fiona, Prachalias, Andreas et al (show 12 more authors)
(2021)
The Impact of <SUP>68</SUP>Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours.
FRONTIERS IN ENDOCRINOLOGY, 12.
654975-.
Abstract
<h4>Objective</h4>Pancreatic neuroendocrine tumours (panNETs) arise sporadically or as part of a genetic predisposition syndrome. CT/MRI, endoscopic ultrasonography and functional imaging using Octreoscan localise and stage disease. This study aimed to evaluate the complementary role of <sup>68</sup>Gallium (<sup>68</sup>Ga)-DOTA PET/CT in managing patients with panNETs.<h4>Design</h4>A retrospective study conducted across three tertiary UK NET referral centres.<h4>Methods</h4>Demographic, clinical, biochemical, cross-sectional and functional imaging data were collected from patients who had undergone a <sup>68</sup>Ga-DOTA PET/CT scan for a suspected panNET.<h4>Results</h4>We collected data for 183 patients (97 male): median (SD) age 63 (14.9) years, 89.1 <i>vs.</i> 9.3% (n=163 vs. 17) alive <i>vs.</i> dead (3 data missing), 141 sporadic <i>vs.</i> 42 familial (MEN1, n=36; 85.7%) panNETs. Non-functional <i>vs.</i> functional tumours comprised 73.2 <i>vs.</i> 21.3% (n=134 <i>vs.</i> 39) (10 missing). Histological confirmation was available in 89% of individuals (n=163) but tumour grading (Ki67 classiifcation) was technically possible only in a smaller cohort (n=143): grade 1, 50.3% (n=72); grade 2, 46.2% (n=66) and grade 3, 3.5% (n=5) (40 histopathological classification either not technically feasible or biopsy not perfomed). 60.1% (n=110) were localised, 14.2% (n=26) locally advanced and 23.5% (n=43) metastatic (4 missing). 224 <sup>68</sup>Ga-DOTA PET/CT scans were performed in total for: diagnosis/staging 40% (n=88), post-operative assessment/clinical surveillance 53% (n=117) and consideration of peptide receptor radionuclide therapy (PRRT) 8% (n=17) (2 missing). PET/CT results confirmed other imaging findings (53%), identified new disease sites (28.5%) and excluded suspected disease (5%). Overall, <sup>68</sup>Ga-DOTA PET/CT imaging findings provided additional information in 119 (54%) patients and influenced management in 85 (39%) cases.<h4>Conclusion</h4><sup>68</sup>Ga-DOTA PET/CT imaging more accurately stages and guides treatment in patients with sporadic/familial panNETs with newly diagnosed/recurrent disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | pancreatic neuroendocrine tumours, (68)Gallium DOTA PET, CT, functional imaging, multiple endocrine neoplasia type 1, sporadic and familial |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 01 Jul 2021 14:49 |
| Last Modified: | 18 Oct 2023 15:02 |
| DOI: | 10.3389/fendo.2021.654975 |
| Open Access URL: | https://www.frontiersin.org/articles/10.3389/fendo... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3128440 |
Dimensions
Dimensions
